These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 9703279)

  • 1. Interaction of thalidomide, phthalimide analogues of thalidomide and pentoxifylline with the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid: concomitant reduction of serum tumour necrosis factor-alpha and enhancement of anti-tumour activity.
    Ching LM; Browne WL; Tchernegovski R; Gregory T; Baguley BC; Palmer BD
    Br J Cancer; 1998 Aug; 78(3):336-43. PubMed ID: 9703279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thalidomide increases both intra-tumoural tumour necrosis factor-alpha production and anti-tumour activity in response to 5,6-dimethylxanthenone-4-acetic acid.
    Cao Z; Joseph WR; Browne WL; Mountjoy KG; Palmer BD; Baguley BC; Ching LM
    Br J Cancer; 1999 May; 80(5-6):716-23. PubMed ID: 10360649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Suppression of serum tumour necrosis factor-alpha by thalidomide does not lead to reversal of tumour vascular collapse and anti-tumour activity of 5,6-dimethylxanthenone-4-acetic acid.
    Browne WL; Wilson WR; Baguley BC; Ching LM
    Anticancer Res; 1998; 18(6A):4409-13. PubMed ID: 9891501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of 3-fluorothalidomide and 3-methylthalidomide enantiomers on tumor necrosis factor production and antitumor responses to the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
    Chung F; Palmer BD; Muller GW; Man HW; Kestell P; Baguley BC; Ching LM
    Oncol Res; 2003; 14(2):75-82. PubMed ID: 14649541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Consequences of increased vascular permeability induced by treatment of mice with 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and thalidomide.
    Chung F; Liu J; Ching LM; Baguley BC
    Cancer Chemother Pharmacol; 2008 Mar; 61(3):497-502. PubMed ID: 17473922
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modulation of the pharmacokinetics of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice by thalidomide.
    Kestell P; Zhao L; Baguley BC; Palmer BD; Muller G; Paxton JW; Ching LM
    Cancer Chemother Pharmacol; 2000; 46(2):135-41. PubMed ID: 10972483
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 5,6-dimethylxanthenone-4-acetic acid (DMXAA): a new biological response modifier for cancer therapy.
    Zhou S; Kestell P; Baguley BC; Paxton JW
    Invest New Drugs; 2002 Aug; 20(3):281-95. PubMed ID: 12201491
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of thalidomide on tumour necrosis factor production and anti-tumour activity induced by 5,6-dimethylxanthenone-4-acetic acid.
    Ching LM; Xu ZF; Gummer BH; Palmer BD; Joseph WR; Baguley BC
    Br J Cancer; 1995 Aug; 72(2):339-43. PubMed ID: 7640215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of tumour necrosis factor-alpha by single and repeated doses of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid.
    Philpott M; Baguley BC; Ching LM
    Cancer Chemother Pharmacol; 1995; 36(2):143-8. PubMed ID: 7767951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NF-kappa B activation in vivo in both host and tumour cells by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
    Woon ST; Zwain S; Schooltink MA; Newth AL; Baguley BC; Ching LM
    Eur J Cancer; 2003 May; 39(8):1176-83. PubMed ID: 12736120
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of the serotonin receptor antagonist cyproheptadine on the activity and pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
    Zhao L; Kestell P; Philpott M; Ching LM; Zhuang L; Baguley BC
    Cancer Chemother Pharmacol; 2001 Jun; 47(6):491-7. PubMed ID: 11459201
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulation of thalidomide pharmacokinetics by cyclophosphamide or 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice: the role of tumour necrosis factor.
    Chung F; Wang LC; Kestell P; Baguley BC; Ching LM
    Cancer Chemother Pharmacol; 2004 May; 53(5):377-83. PubMed ID: 15060740
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral activity and pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice.
    Zhao L; Kestell P; Ching LM; Baguley BC
    Cancer Chemother Pharmacol; 2002 Jan; 49(1):20-6. PubMed ID: 11855749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The antitumour activity of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF receptor-1 knockout mice.
    Zhao L; Ching LM; Kestell P; Baguley BC
    Br J Cancer; 2002 Aug; 87(4):465-70. PubMed ID: 12177785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumour activity of the novel immune modulator 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice lacking the interferon-gamma receptor.
    Pang JH; Cao Z; Joseph WR; Baguley BC; Ching LM
    Eur J Cancer; 1998 Jul; 34(8):1282-9. PubMed ID: 9849492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of intratumoral tumor necrosis factor (TNF) synthesis and hemorrhagic necrosis by 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF knockout mice.
    Ching LM; Goldsmith D; Joseph WR; Körner H; Sedgwick JD; Baguley BC
    Cancer Res; 1999 Jul; 59(14):3304-7. PubMed ID: 10416582
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancement of the anti-tumour effects of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugs.
    Lash CJ; Li AE; Rutland M; Baguley BC; Zwi LJ; Wilson WR
    Br J Cancer; 1998 Aug; 78(4):439-45. PubMed ID: 9716024
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The antitumour agent 5,6-dimethylxanthenone-4-acetic acid acts in vitro on human mononuclear cells as a co-stimulator with other inducers of tumour necrosis factor.
    Philpott M; Ching LM; Baguley BC
    Eur J Cancer; 2001 Oct; 37(15):1930-7. PubMed ID: 11576850
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potentiation of the anti-tumour effect of hyperthermia by combining with the vascular targeting agent 5,6-dimethylxanthenone-4-acetic acid.
    Murata R; Overgaard J; Horsman MR
    Int J Hyperthermia; 2001; 17(6):508-19. PubMed ID: 11719967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stimulation of tumors to synthesize tumor necrosis factor-alpha in situ using 5,6-dimethylxanthenone-4-acetic acid: a novel approach to cancer therapy.
    Joseph WR; Cao Z; Mountjoy KG; Marshall ES; Baguley BC; Ching LM
    Cancer Res; 1999 Feb; 59(3):633-8. PubMed ID: 9973211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.